1. Beovu® [Summary of Product Characteristics], Basel, Switzerland, Novartis Pharma A.G. Sep 2020. www.ema.europa.eu/en/documents/product-information/beovu-epar-product-information_en.pdf. Accessed 18 Jul 2022.
2. Beovu® [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; May 2022. https://www.novartis.us/sites/www.novartis.us/files/beovu.pdf. Accessed 18 Jul 2022.
3. Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72–84.
4. Safety of Beovu® (brolucizumab). https://www.brolucizumab.info/. Accessed 07 Oct 2022.
5. Monés J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021;128(7):1050–9.